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Abstract
Background: In many but not in all neuropsychological studies buprenorphine-treated opioid-dependent patients
have shown fewer cognitive deficits than patients treated with methadone. In order to examine if hypothesized
cognitive advantage of buprenorphine in relation to methadone is seen in clinical patients we did a
neuropsychological follow-up study in unselected sample of buprenorphine- vs. methadone-treated patients.
Methods: In part I of the study fourteen buprenorphine-treated and 12 methadone-treated patients were tested
by cognitive tests within two months (T1), 6-9 months (T2), and 12 - 17 months (T3) from the start of opioid
substitution treatment. Fourteen healthy controls were examined at similar intervals. Benzodiazepine and other
psychoactive comedications were common among the patients. Test results were analyzed with repeated
measures analysis of variance and planned contrasts. In part II of the study the patient sample was extended to
include 36 patients at T2 and T3. Correlations between cognitive functioning and medication, substance abuse, or
demographic variables were then analyzed.
Results: In part I methadone patients were inferior to healthy controls tests in all tests measuring attention,
working memory, or verbal memory. Buprenorphine patients were inferior to healthy controls in the first working
memory task, the Paced Auditory Serial Addition Task and verbal memory. In the second working memory task, the
Letter-Number Sequencing, their performance improved between T2 and T3. In part II only group membership
(buprenorphine vs. methadone) correlated significantly with attention performance and improvement in the Letter-
Number Sequencing. High frequency of substance abuse in the past month was associated with poor performance
in the Letter-Number Sequencing.
Conclusions: The results underline the differences between non-randomized and randomized studies comparing
cognitive performance in opioid substitution treated patients (fewer deficits in buprenorphine patients vs. no
difference between buprenorphine and methadone patients, respectively). Possible reasons for this are discussed.
Background
Opioid agonists buprenorphine and methadone prevent
opioid withdrawal symptoms and reduce craving for
opioids [1,2]. Both drugs are used in opioid substitution
treatment (OST), also known as opioid maintenance
treatment. OST has proven effective in reducing illicit
drug use, somatic diseases, mortality, and social or
mental health problems in opioid-dependent patients
[3,4]. Cognitive effects of OST drugs have been exam-
ined in clinical and experimental studies, but the results
have been mixed. Studies comparing OST patients
against healthy controls have, in general, shown cogni-
tive impairment among patients [5-8]. Yet, it has not
been proven that the impairment would be specifically
related to opioid substitution drugs [5,9,10]. In non-ran-
domized studies, however, buprenorphine-treated
* Correspondence: pekka.rapeli@hus.fi
1Department of Psychiatry. Helsinki University Central Hospital, Finland
Full list of author information is available at the end of the article
Rapeli et al. BMC Clinical Pharmacology 2011, 11:13
http://www.biomedcentral.com/1472-6904/11/13
© 2011 Rapeli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.opioid-dependent patients have performed better than
methadone patients in several cognitive tests [7,11-13].
It is important to know if the possible cognitive differ-
ences between unselected buprenorphine vs. methadone
patients are stabile during the treatment and what are
the correlates of cognitive performance. Therefore, we
compared cognitive performance of buprenorphine and
methadone patients against healthy controls thrice (T1 -
T3) during the first year in the OST by (part I of the
study). In part II we analyzed correlates of cognitive per-
formance in patients after six (T2) and twelve (T3)
months in treatment by using extended patient pool.
The present study is an extension to our previous stu-
dies [7,14].
Part I: Stability
Opioid and dopamine systems in the brain have impor-
tant interactions, and current opioid drug use may nega-
tively affect cognitive functioning, especially working
memory [15-17]. However, Pirastu et al. have presented
evidence that buprenorphine as being a partial mu
opioid agonist and kappa opioid receptor antagonist
may improve cognitive performance after long-term
opioid abuse. According to them methadone as being a
full mu opioid agonist may lack properties for support-
ing normal cognitive function [18]. Also, there is evi-
dence that adverse interactive effects benzodiazepines
(BZD) and opioid substitution drugs on cognitive per-
formance are greater for methadone than buprenorphine
[19,20]. Therefore, we hypothesized that patients treated
with buprenorphine combined in most cases with BZD
and other comedications would show greater cognitive
improvement in long-term treatment in comparison to
methadone-treated ones.
Part II: correlates
In the part II of the study the patient sample was
extended to include additional patients examined at all
t e s tp o i n t s ,b u tw h o s ed a t aw e r ee x c l u d e da tT 1 .A f t e r
this, data from 36 patients could be analyzed at T2 and
T3. We hypothesized that there would be negative cor-
relations between medication variables (opioid agonist
dose, BZD dose, and the number of psychoactive drugs)
and cognitive performance in opioid-dependent patients
treated either with buprenorphine or methadone. In
addition, we hypothesized that those with the highest
opioid dose would have higher BZD doses, because
BZDs have been associated with craving for higher
opioid dose [21]. The negative effects of methadone and
buprenorphine on cognition are dose-dependent in
healthy volunteers, although little is known about the
development of tolerance [22,23]. It is known that BZDs
have negative effects on memory performance in opioid
substitution treated patients, and these effects are
stronger for methadone than for buprenorphine [24].
Little is known about possible effects of polypharmacy
on cognition in opioid-agonist treated patients. How-
ever, in other patient populations, those patients treated
with several drugs perform worse in cognitive tests than
patients treated with single drug [25-27].
Negative correlations were also hypothesized between
cognitive performance and frequency of substance abuse
in the past month, benzodiazepine dosage, the number
of other psychoactive drugs, early onset of substance
abuse, early-onset mental health or behavioral problems,
opioid-related overdoses, and duration of lifetime alco-
hol abuse. In our sample recent alcohol and/or cannabis
abuse were common, and these negatively affect cogni-
tive function [28-31]. Early onset substance abuse and
childhood mental health or behavioral problems have
been associated with poor adult cognitive functioning
among individuals with substance abuse problems
[32-35]. High number of opioid-related overdoses, life-
time alcohol abuse, and low level of education have all
been associated with poor cognitive performance among
opioid-dependent patients [5,36,37]. Verbal intelligence
(IQ) and years of education were hypothesized to corre-
late positively with memory performance.
Methods
All participants included in the study were between 18 -
50 years of age and participated voluntarily. Inclusion
criteria for patients were opioid dependence and BZD
dependence or abuse according to Diagnostic and Statis-
t i c a lM a n u a lo fM e n t a lD i s o r ders (DSM-IV), treatment
of opioid dependence with methadone, buprenorphine,
or buprenorphine/naloxone. We excluded participants
with uncontrolled polysubstance abuse, acute alcohol
abuse, or acute axis I psychiatric morbidity according to
DSM-IV other than substance abuse disorders. Full
description of our inclusion and exclusion criteria is
given in our previous report [7].
In order to screen for substance abuse an urine sam-
ple was collected from each patient on each day of test-
ing and at least once in the preceding week. Each
healthy control participant was screened for substance
abuse once during the study period. In addition, we
interviewed all participants about their past month and
lifetime substance use by using the European Addiction
Severity Index as a basis for further inquiry [38]. If any
indication of intoxication was observed, we excluded
them. Breath alcohol testing was used when considered
necessary. Participants who had used within 24 h alco-
hol more than four/five drinks (females/males, respec-
tively) or significant as-needed benzodiazepine dose (5
mg or more as diazepam equivalent dose) were excluded
as well. The study protocol was accepted by the Ethics
Committee of Helsinki University Central Hospital. We
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Declaration of Helsinki from all participants, and paid
them € 60 if they attended all study visits.
Part I participants
Participants who were eligible for T1-T3 follow-up (sam-
ple I) represent 42% (14/35) of the all buprenorphine
patients tested at T1, 55% (12/22) of the methadone
patients and 78% (14/18) of the healthy controls, respec-
tively. To test whether the follow-up completers of either
group were significantly different from the non-completers
of that group, we compared these groups by independent
samples t-tests, chi-square tests, or Mann-Whitney U-tests
(p-value = 0.05). No statistically significant differences
emerged in demographic, medication or cognitive vari-
ables. Because there were few follow-up non-completers
(n = 4) among the potential healthy controls, these com-
parisons were not made in healthy controls.
When the groups were compared on demographic
variables with analysis of variance (ANOVA) or chi-
square-test (Table 1) there were no statistically signifi-
cant differences in age, sex, or estimated premorbid
intelligence. Healthy controls had completed more years
in education than either one of the patient groups.
Because BZD use on prescription was very common,
their doses were converted to diazepam equivalent doses
according to the conversion tables given by Nelson and
Chouinard [39]. Temazepam doses were halved in order
to account for their use as hypnotics on the night before
testing. Substance abuse in the past month was esti-
mated as frequency of use. Because accurate number of
the days of abuse was hard to obtain we dichotomized
the frequency of the past month substance abuse into
two categories. The first category was labeled as low to
moderate use, and it included abstinence or substance
abuse up to two days a week. The second category was
labeled as high frequency group and included all the
participants with substance use of three days a week or
more. This classification was based on the findings
showing that mean three days of substance use a week
is one of the threshold values for getting into serious
substance abuse problems [40,41]. In the buprenorphine
group, 79% of the patients were given buprenorphine/
naloxone at all test points. Thus, they were also given
sublingual naloxone in the ratio 1:4 combined with their
buprenorphine dose. When the tablet is taken sublin-
gually the absorption of naloxone is low and eliminates
within first hours [42]. It has been concluded that
naloxone has minimal, if any effect, on the bioavailabil-
ity or pharmacokinetics of buprenorphine [43,44]. Also,
buprenorphine and buprenorphine/naloxone have simi-
lar physiological effects [43]. On the basis of these find-
ings, we combined patients using either one of the
buprenorphine compounds. Table 2 shows medication
characteristics of the sample I within the last 24 h
before testing. Both patient groups used more psychoac-
tive medications than healthy controls.
Part II participants
Sample II (n = 36) included 51% of all the buprenor-
phine-treated and 59% of methadone-treated patients
who entered the follow-up at T1. The methadone group
included also five patients who were tested without
opioid medication at T1, but who then started metha-
done treatment within few days after the testing. Thus,
all patients were tested after minimum 6 (T2) and 12
months (T3) of OST. They had been tested at start of
their treatment, but were excluded from the part I sam-
ple. Substance abuse history variables included in the
analyses were onset ages of any substance and opioid
abuse, years of heavy alcohol use, and the number of
self-reported opioid-related overdoses. Whenever possi-
ble, the data was checked using medical reports. It
turned out that no reliable information about the num-
ber of opioid-related overdoses could be obtained.
Therefore this variable was excluded from the analyses.
Current substance abuse variables were frequency of
substance abuse in the past month (low vs. high) and
drug screen result (positive vs. negative). Medication
drug use variables that were examined included opioid
substitution drug (buprenorphine vs. methadone), ben-
zodiazepine dose (diazepam equivalent), and the number
of other psychoactive drugs other than opioid substitu-
tion drug. Demographic variables included in the ana-
lyses were age, sex, years of education, early
neurobehavioral problems, and verbal IQ. Data about
childhood mental health or behavioral problems was
gathered using the Childhood Behavioral Checklist as a
basis for interview, and medical reports were used,
whenever possible [45]. Those participants who had had
treatment or referral to special services due to mental
health or behavioral problems before the onset of sub-
stance abuse were rated as early-onset neurobehavioral
problem group (31%). If significant change was seen in
cognitive performance then change (T3 - T2) in that
that variable, as well in medication, and substance use
changes were analyzed. Medication and substance abuse
change variables were made more reliable by dichoto-
mizing the data. Change in opioid drug dose between
T2 and T3 was dichotomized as steady or reduced dose
group (58%) or higher dose group (42%). Change in
BZD dose between T2 and T2 was grouped respectively.
The majority of the patients belonged to steady or
r e d u c e dB Z Dd o s eg r o u p( 8 3 % ) ,a n dt h er e s t( 1 7 % )h a d
higher BZD dose at T3. All those who reduced their fre-
quency of substance abuse as indicated by the shift from
the high frequency group to low to moderate frequency
group were put into group of reduced substance abuse.
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the low to moderate frequency group at both time
points, totaling 58% of the patients. The rest were put
into group of non-reduced substance abuse (42%).
Change in the number of psychoactive drugs was
dichotomized similarly. All those with less psychoactive
drugs at T3 in comparison to T2 or no other psychoac-
tive prescribed drugs than opioid drug at both time
points were put in the group of reduced use of psy-
choactive drugs (42%). The rest were put into group of
non-reduced use of psychoactive drugs (58%). Table 3
presents the demographic characteristics of the sample
II. In the buprenorphine group, 78% of the patients
were given buprenorphine/naloxone at all test points.
Table 4 shows other medication characteristics of the
sample II within the last 24 h before testing.
Procedure
Cognitive tests were administered between three to six
hours after opioid substitution drug had been given.










Age (M ± SD) 3 0±7 3 1±8 2 9±1 0 ns
Sex (female/male) 36%/64% 50%/50% 50%/50% ns
Intelligence
a (M±S D ) 101 ± 11 98 ± 9 105 ± 8 ns
Education, years 10 ± 2 10 ± 1 13 ± 1 BN & M < HC ***
Main opioid of abuse used within last month at T1 (%)
Buprenorphine 93% 83%? - ns
b
Heroin 7% 17% - ns
b
Days in opioid substitution treatment at test (M±S D )
T1 21 ± 15 20 ± 14 - ns
b
T2 210 ± 20 200 ± 28 - ns
b
T3 414 ± 46 405 ± 31 - ns
b
Examined in inpatient settings %
T1 21% 25% - ns
b
T2 7% 0% - ns
b
T3 7% 8% - ns
b
Participants with high frequency of use of any substance of abuse
c
%
T1 86% 67% 14% BN > HC ***; M > HC *
T2 29% 42% 7% ns ; ns
T3 36% 33% 7% ns ; ns
T2 < T1** T3 < T1*
T3 < T1*
Participants with the past month extra doses of any opioid
d,%
T1 86% 92% - ns
b
T2 29% 33% - ns
b
T3 36% 33% - ns
b
T2 < T1** T2 < T1**
T3 < T1* T3 < T1**
Participants with the past month nicotine use (daily)
T1 100% 100% 36% BN & M > HC ***
T2 100% 100% 36% BN & M > HC ***
T3 100% 93% 29% BN > HC **; M > HC ***
Note. BN = buprenorphine patients, HC = healthy control group, and M = methadone patients.
a Estimation based on the vocabulary and picture completion subtests of the Wechsler Adult Intelligence Scale - Revised (WAIS-R) [67].
b Tested only between patient groups.
c High frequency = three or more days a week. Alcohol use was taken into account if it was at least mean weekly 16 portions (12 g) for females and 24 portions
for males or binge drinking occurred on any day.
d Extra doses of any non-prescribed opioid use during the recent month seen in drugs screens or admitted by the patients.
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
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Attentional Performance (TAP) [46]. In the Alertness
test, the participant was instructed to respond to visual
stimuli by pressing a response key as quickly as possible.
The stimuli were presented without or with auditory
warning signal. The condition without warning signal is
a simple reaction time task reflecting tonic alertness.
The condition with auditory warning signal reflects both
tonic and phasic alertness. In the Go/NoGo test, the
participant was instructed to respond only to two out of
five alternative stimuli. Thus, selective attention and
executive control of action was assessed.
Working memory was assessed by two tests. In the
Letter-Number Sequencing task from the Wechsler
Memory Scale - III the participant was instructed to
repeat letters and numbers in specific order [47]. In the
Paced Auditory Serial Addition Task ( PASAT) the par-
ticipant was instructed to add two consecutive numbers
from an auditory series of digit [48]. A new digit was
presented after every 1.6 seconds. Both tests are thought
to tap complex working memory because simultaneous
storage and manipulation of the material is needed.
Verbal memory was assessed by the Logical Memory
from the Wechsler Memory Scale - III. However, only








Group or time point comparison p-
values
Opioid agonist drug, dose
Buprenorphine (M ± SD;
(range) )
T1 16 ± 3 mg
(12 - 24 mg)
-- -
T2 20 ± 5 mg
(14 - 28 mg)
- - T2 > T1**
T3
Methadone (M ± SD;(range) )
21 ± 6 mg
(6 - 28 mg)
- - T3 > T1**








- T2 > T1 ***




- T3 > T1 ***
Participants treated with BZD medication ’
T1 79% 100% 0% BN & M > HC ***
BZD dose at T1 (M ± SD) 20 ± 17 mg 21 ± 11 mg - ns
a
T2 71% 100% 0% BN & M > HC ***
BZD dose at T2 (M ± SD) 16 ± 11 mg 22 ± 11 mg - ns
a
T3 64% 100% 0% BN & M > HC ***
BZD dose at T3 (M ± SD) 13 ± 12 mg 22 ± 9. mg - BN < M *
Number of other medications with possible cognitive
effects
b
(M ± SD (range))






BN & M > HC ***
; M > BN *






BN & M > HC ***






BN & M > HC ***
a Tested only between patient groups.
b These included antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and substance abuse withdrawal symptom or
(non-opioid) pain relievers. There were no significant differences between time points within the groups in medication variables.
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
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is given in our previous report [7].
Statistical analyses: stability of function
Longitudinal changes in cognitive function were exam-
ined by repeated-measures analysis of variance
(ANOVA) using general linear model approach. Group
was used as between-subjects factor and time as within-
subjects factor. Before the analyses normality assump-
tions of cognitive variables were examined by Shapiro-
Wilk’st e s ta n dh o m o g e n e i t yo fv a r i a n c eb yL e v e n e ’s
test. The data were also screened for outlying values.
On the basis of these procedures, reaction time and the
PASAT scores were subjected to log transformations
before further analyses, and the Go/NoGo errors were
examined by non-parametric Kruskal-Wallis ANOVA.
Sphericity assumption was tested by Mauchly’s test, and
when appropriate, analyses of effects were interpreted
using Huynh-Feldt correction. The effects of demo-
graphic variables on cognitive performance were tested
as covariates. Only significant covariates were retained
in the model. Statistically significant between groups
effects were followed by planned contrast using healthy
controls as a reference group. Significant time effects we







Group or time point comparison p-
values
Age, years at T1
(M±S D )
30 ± 8 32 ± 8 ns




101 ± 8 100 ± 11 ns
Education, years
(M±S D )
10 ± 2 11 ± 1 ns
Participants with early neurobehavioral problems % 33% 28% ns
Examined in inpatient settings %
T2 6% 6% ns
T3 11% 11% ns
Participants with high frequency use of any substance of
abuse %
b
T2 44% 39% ns
T3 44% 44% ns
Participants with recent month extra doses of any opioid %
c
T2 36% 36% ns
T3 36% 43% ns
Nicotine, participants using daily, %
T2 100% 100% ns
T3 100% 100% ns
Days in opioid substitution treatment at test (M±S D )
T2 211 ± 19 196 ± 27 ns
T3 411 ± 43 405 ± 29 ns
Age of onset, any substance abuse (M±S D )1 6 ± 4 1 5 ± 3 ns
Age of onset, opioid abuse
(M±S D )
19 ± 5 19 ± 4 ns
Participants with lifetime alcohol abuse 72% 83% ns
Years of any substance abuse at T1 (M±S D )1 5 ± 7 1 7 ± 7 ns




Years of opioid abuse at T1, years (M±S D )1 0 ± 7 1 2 ± 7 ns
a Estimation based on the WAIS-R Vocabulary score.
b High frequency = three or more days a week Alcohol use was considered heavy if it was at least mean weekly 16 portions for females and 24 portions for
males. One portion was defined as 12 g of alcohol.
c Non-prescribed doses of opioids during the recent month seen in drugs screens or admitted by the patient.
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T2). When a significant group by time interaction effect
was noted, it was examined further by combining pre-
vious contrasts (healthy control vs. buprenorphine
group * T2 vs. T1, healthy control vs. buprenorphine
g r o u p*T 3v s .T 2 ;a n dh e a l t h yc o n t r o lv s .m e t h a d o n e
group, respectively). All statistical analyses were done by
SPSS statistical software, version 15.0, with an exception
of the effect size calculations. These were done by an
effect size calculator provided by Durham University,
UK [49]. For the effect size estimation we pooled the
samples and corrected the values by Hedge’s correction
for small sample bias.
Statistical analyses: correlates of cognitive functioning
Cognitive tests selected for the analyses were the same
as in the part I, except that the PASAT was excluded
from the second set of analyses. Improvement in the
PASAT is shown to be related to practice effect [50].
This makes it problematic to analyze the correlates of
this measure in repeated testing. In order to reduce the
number of cognitive variables correlations between the
variables analyzed, and whenever justified, domain-wise
cognitive sum scores for T2 and T3 performances were
formed. T2 performance was used as a reference point
in T3 summed scores. Analysis of correlation is sensitive
for the effects of outliers. Therefore, visual inspections
of scatter plots were used to check the linearity of the
relationship between variables and the role of possible
outliers. Then correlations between cognitive variables
we analyzed by the Pearson product moment method.
As expected there were high positive correlations
between all reaction time measures at both test points
(range .52 - .86); whereas correlations between reaction
time measures and other cognitive measures ranged
from zero to moderate (-.38 as highest). Therefore, a
mean composite score called attention performance was
calculated after converting the test scores into z-scores.
The working memory measure, the Letter-Number
Sequencing task, showed only low to moderate correla-
tions with other measures (.38 as highest) and therefore
it was not combined with other measures. The verbal
memory measures, immediate and delayed recall of the
L o g i c a lM e m o r y ,c o r r e l a t e ds t r o n g l ya tb o t ht e s tp o i n t s
(.80 at T2 and .91 at T3). Therefore, a mean sum score
called verbal memory was formed after z-score conver-
sion. Then group differences in cognitive function were
examined by repeated-measures analysis of variance







Group or time point comparison p-
values
Opioid drug, dose
(M ± SD (range) )
T2 22 ± 5 mg
( 10 - 28 mg)
- T2 vs. T3, ns
T3 21 ± 6 mg
( 6 - 30 mg)
-
T2 - 119. ± 33 mg
(80 - 180 mg)
T2 vs. T3, ns
T3 - 129 ± 33 mg
(75 - 180 mg)
Participants using BZD medication
T2/T3 78%/67% 89%/94% ns/ns
BZD dose at T2 (M ± SD (range)) 20 ± 16 mg
(0 - 60 mg)
21 ± 16 mg
(0 - 70 mg)
T2 vs. T3, ns
ns
BZD dose at T3 (M ± SD (range)) 16 ± 14 mg
(0 - 40 mg)
20 ± 10 mg
(0 - 40 mg)
ns
T2 vs. T3, ns
Number of other medications with possible cognitive
effects
a
T2/T3 (M ± SD ; (range)) 1.8 ± 1.1 (0 - 3) 2.2 ± 0.7 (1
-4)
ns
1.9 ± 1.4 (0 - 4) 2.0 ± 1.0 (1 -
4)
ns
T2 vs. T3, ns
These included antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and substance abuse withdrawal symptom or
(non-opioid) pain relievers.
C = controls, M = methadone, BN = buprenorphine or buprenorphine/naloxone
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
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was used as between-subjects factor and time as within-
subjects factor. After this all significant or three highest
correlates of each cognitive variable were further exam-
ined by checking for intercorrelations between these
variables and other variables of interest. Also, medica-
tion variables were checked for significant intercorrela-
tions. The sample size did not allow for multiple
regression analysis. Instead three highest correlations for
each cognitive domain were investigated with analyses
of semipartial correlations. Correlations between .10 -
.19 were considered to show low association and .20 -
29 mild association. Only some of these are reported.
Correlations between, .30 - .49 were considered to show
moderate association, .50 - 69 substantial and those .70
or above a strong association [51].
Results
Stability of cognitive functioning in sample I
The pattern of means in Table 5 identifies change over
time in cognitive performance in each group. There
were statistically significant overall group differences in
all attention and memory measures. As apparent from
the Table 5, the methadone-treated patient group con-
stantly lagged behind the healthy control group in the
TAP reaction time tests measuring alertness and selec-
tive attention. Planned contrasts confirmed that the
healthy controls outperformed the methadone group in
these measures (p = 0.002 for the TAP tonic alertness/
simple reaction time; p = 0.002 for the TAP phasic
alertness/reaction time with-auditory-warning-signal;
and p = 0.001 for the TAP Go/NoGo reaction time/
selective attention). There were neither significant time
nor group by time interaction effects in these measures.
Errors in the Go/NoGo task were rare in all groups, and
no significant between groups differences were observed.
In both working memory measures there was an overall
group effect. In the PASAT the planned contrast
revealed that both patient groups performed overall
worse than the healthy controls at the level of p =
0.001. In the Letter-Number Sequencing the values were
p = 0.016, for healthy controls vs. buprenorphine
patients and p = 0.008 for healthy controls vs. metha-
done patients. However, because there was also time
effect (the PASAT), or a group by time interaction effect
(the Letter-Number Sequencing) in these measures,
further analyses are needed before the final interpreta-
tion. In the PASAT the improvement in overall perfor-
mance between T1 and T2 turned out to be non-
significant, but the overall improvement between T2
and T3 was significant, p = 0.01. As apparent from Fig-
ure 1, the source of group by time interaction in the
Letter-Number Sequencing was due to differences
between the groups between T2 and T3. This was con-
firmed by a planned contrast which showed improved
performance in the buprenorphine patients between T2
and T3 relative to healthy control group, p = 0.017.
Effect size of the T2 - T3 improvement in the buprenor-
phine group, as measured by Cohen’s d, was 0.77. In
verbal memory, there was a significant overall group
effect both in immediate and delayed condition of the
Logical Memory. Both patient groups performed worse
than the healthy controls in the immediate Logical
Memory, p = 0.029 for the buprenorphine group; and p
= 0.007 for the methadone group. In the delayed Logical
Memory the values were p = 0.005, and p =0 . 0 2 8 ,
respectively.
Cognitive functioning in sample II
The cognitive group comparisons in the part II (T2 -
T3) sample brought results that were in line with the
part I sample analyses. Buprenorphine patients outper-
formed methadone patients in the combined attention
performance (p = 0.004), and no significant time or
group by time effect were seen. In working memory as
measured by the Letter-Number Sequencing there was a
main effect of time (p = 0.01) and a significant group by
time interaction, (p = 0.04) indicating again that
improvement in this measure was due to enhanced per-
formance in the buprenorphine patients between T2
and T3. In the combined verbal memory measure there
were no significant differences between groups, time
effect, or group by time interaction.
Correlations between medication variables and non-
cognitive variables in sample II
At T2, buprenorphine dose correlated substantially with
BZD dose (.62, p = 0.006) and moderately with the
number of psychoactive drugs (.40, ns). In the metha-
done group, respective values were (.47, ns; and .58, p =
0.013). At T3, buprenorphine dose correlated at moder-
ate level with BZD dose (.33, ns) and at very low level
with the number of psychoactive drugs (.10, ns). In the
methadone group respective values were mild (.25, ns;
a n d. 2 0 ,n s ) .I ng e n e r a l ,b u p r e n o r p h i n eo rm e t h a d o n e
doses did not show significant correlations with sub-
stance abuse or demographic variables. As an exception
buprenorphine dose correlated negatively with years of
alcohol abuse, at T2 the value was -.56 (p = 0.016) and
at T3 -.64 (p = 0.004). In the methadone group, no sig-
nificant correlations emerged. Other significant correla-
tions between medication variables and other non-
cognitive variables of interest are presented in Table 6.
It can be noted that high BZD dose was associated with
high frequency of substance abuse in the past month
and younger age at both time points.
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As shown in Table 7, the only significant correlate for
attention performance at both test points was the opioid
substitution drug group. High frequency of substance
abuse correlated negatively with the Letter-Number
Sequencing performance at both time points. Figures 2
and 3 depict this association. It can be noted from these
Figures that the association between working memory
performance and frequency of substance abuse in the
past month is similar in both groups. The T2 negative
correlation remained significant after controlling for two
next highest correlates. The T3 correlation dropped to
non-significant level after controlling for two next high-
est correlates (-.18). At T3, high benzodiazepine dose
correlated negatively with the Letter-Number
Sequencing performance. After controlling for the two
other highest correlates, this association was no longer
significant (-.22). In further analysis no evidence in sup-
port of high association between BZD dose and the Let-
ter-Number Sequencing performance was seen, because
T2 correlation between these variables was at zero level
(.02). Belonging to the buprenorphine group was the
only variable that correlated significantly (.34) with
change of the Letter-Number Sequencing performance.
After controlling for two other highest correlates, this
association was no longer significant.
The number of psychoactive drugs correlated positively
with verbal memory performances at both testing points.
At T3, the positive association with the number of psy-
choactive drugs reached significant level after two other
Table 5 Group comparisons of cognitive performances using repeated measures ANOVA in sample I
TAP Tonic Alertness/simple reaction time (ms)
T1 232 ± 25 261 ± 21 238 ± 22 Group, p = 0.002
T2 236 ± 18 263 ± 21 233 ± 21
a Time, ns
T3 242 ± 25 267 ± 36 241 ± 25 Group × Time, ns
TAP Phasic Alertness/ reaction time with warning signal (ms)
T1 227 ± 24 244 ± 20 226 ± 21 Group, p = 0.005
T2 229 ± 21 255 ± 28 224 ± 21
a Time, ns
T3 229 ± 19 254 ± 45 225 ± 22 Group × Time, ns
TAP Go-NoGo reaction time (ms)
T1 490 ± 50 548 ± 74 460 ± 41 Group, p = 0.001
T2 480 ± 42 548 ± 104 443 ± 72
a Group, p = 0.002
T3 493 ± 43 529 ± 63 462 ± 47 Age, p = 0.022
Time, ns
Group × Time, ns
TAP Go-NoGo errors
T1 1.1 ± 1.3 0.7 ± 0.6 0.5 ± 0.5 ns
T2 0.5 ± 0.7 1.0 ± 0.9 0.5 ± 0.8
a ns
T3 0.6 ± 0.8 0.5 ± 1.0 0.2 ± 0.4 ns
The Letter-Number Sequencing
T1 8.4 ± 2.2 9.3 ± 2.4 11.8 ± 3.4 Group, p = 0.009
T2 8.8 ± 2.2 8.5 ± 2.3 11.6 ± 3.0 Time, ns
T3 10.6 ± 2.2 8.8 ± 2.4 11.2 ± 3.2 Group × Time, p = 0.007
The PASAT
T1 32.4 ± 10.5 31.0 ± 8.5 46.3 ± 9.7 Group, p = 0.001
T2 35.0 ± 6.8 33.4 ± 10.1 45.8 ± 9.0
a Time, p = 0.013
T3 35.8 ± 10.0 34.9 ± 11.0 49.8 ± 8.4 Group × Time, ns
Logical memory, immediate
T1 12.8 ± 2.6 14.9 ± 4.5 15.9 ± 3.3 Group, p = 0.016
T2 13.8 ± 3.1 14.8 ± 3.7 16.3 ± 3.2 Time, ns
T3 15.5 ± 4.1 14.3 ± 4.3 17.9 ± 2.9 Group × Time, ns
Logical memory, delayed
T1 11.8 ± 3.0 13.1 ± 4.0 13.9 ± 4.0 Group, p = 0.013
T2 12.0 ± 4.0 13.7 ± 4.0 15.6 ± 3.1 Time, ns
T3 12.4 ± 4.1 11.8 ± 4.7 15.9 ± 3.6 Group × Time, ns
Bold indicates statistically significant effects.
a One missing value was replaced by the carry-over value from the preceding testing point.
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negative association with the highly frequent past month
substance abuse and verbal memory performance. After
controlling for two other highest this correlation dropped
to non-significant level (.28). Furthermore, at T3 the cor-
relation between highly frequent substance abuse in the
past month and verbal memory was very low and to the
opposite direction (-.08).
Correlations between opioid substitution drug dose
and cognitive performances opioid drug doses could be
examined only group-wise (n = 18 in both groups).
None of the correlations reached statistical significance.
Because there was a significant group by time interac-
tion in the Letter-Number Sequencing indicating speci-
fic improvement in this task in the buprenorphine
group, correlates for the improvement in the buprenor-
phine group were examined. No significant correlates
for the change score emerged.
Discussion
This study was designed to evaluate stability and correlates
of cognitive functioning in unselected buprenorphine- vs.
methadone treated opioid-dependent patients during the
first year in OST. The main findings are the following.
Buprenorphine-treated opioid-dependent patients do not
show deficits in attention, improve in one of the working
memory tests, the Letter-Number Sequencing, but they
show stable deficits in the other working memory test, the
PASAT, and verbal memory. Methadone-treated opioid-
dependent patients show stabile cognitive deficits in atten-
tion, working memory, and verbal memory. When corre-
lates of cognitive performances are analyzed 6 and 12 after
the start of the OST drug type (buprenorphine vs. metha-
done) is moderately associated with attention perfor-
mance. Highly frequent substance abuse in the past
month is negatively associated with performance in the
Letter-Number Sequencing. The number of other psy-
choactive drugs and verbal IQ both show mild positive
correlation with verbal memory.
Stability of buprenorphine patients’ cognitive function
during the first year in treatment
Our observation of no reaction time deficits in bupre-
norphine-treated opioid-dependent patients in relation
to healthy controls is in accordance with the idea that
some of the negative effects of buprenorphine on cogni-
tion disappear after the development of tolerance. Most
patients had abused buprenorphine before the treatment
(Table 1). Further studies are needed to examine if
buprenorphine patients’ normal performance in atten-
tion tests is related to the development of tolerance
only, or if a population selection process is affecting per-
formance in patient samples.
Our finding of partial recovery of working memory
function in buprenorphine-treated patients during the
OST is in line with the idea of Spiga et al. [52]. The idea
is supported by observations by Pirastu et al. showing
that buprenorphine patients outperform methadone
patients in spatial working memory [18]. They suggest
that buprenorphine could preserve working memory
function better than methadone because of its antagon-
ism on kappa opioid receptor, which then affects prefron-
tal dopamine tone known to be important for working
memory. This reasoning, however, does not explain why
t h ei m p r o v e m e n ti nw o r k i n gm e m o r yi no u rs t u d yt o o k































































Figure 1 Group performances in the Letter-Number
Sequencing Task during the study period in sample I.
Table 6 Significant correlations between medication variables and other non-cognitive variables in sample II
Medication variables Substance abuse variables Demographic variables
Benzodiazepine dose (T2) Frequency of substance abuse in the past month
.36 ( p = 0.033)
Age
-.34 (p = 0.040)
Benzodiazepine dose (T3) Frequency of substance abuse in the past month
.50 (p = 0.002)
Age
-.33 (p = 0.048)
Number of other psychoactive drugs (T2)
Number of other psychoactive drugs (T3) Years of opioid abuse
-.37 (p = 0.028)
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Bold indicates statistically significant correlation.
Figure 2 Correlation between the frequency of the past month
substance abuse and the performance in the Letter-Number
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Figure 3 Correlation between the frequency of the past month
substance abuse and the performance in the Letter-Number
Sequencing at T3 in sample II.
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both patient groups are inferior to healthy controls
while all groups show improvement during the study
period. Improvement that is seen in all groups is a nor-
mal finding when the PASAT is administered, and most
likely reflects practice effect [50]. The result of no speci-
fic improvement in the buprenorphine patients in this
measure may be related to the finding that also several
other cognitive processes than working memory are
needed for good performance in the PASAT [53].
In verbal memory buprenorphine-treated patients per-
f o r mw o r s et h a nh e a l t h yc o n t r o l sd u r i n gt h ew h o l ef o l -
low-up. Buprenorphine dose given to our patients was
relative high (range mean 16 mg (T1) - 21 mg (T3)).
High dose of buprenorphine (32 mg) have been asso-
ciated with verbal memory impairment [54]. In addition,
in recent study by Messinis et al. buprenorphine-treated
opioid-dependent patients with a fairly low mean dose
of buprenorphine (7 mg) performed worse than healthy
controls in verbal memory. Abstinent opioid-dependent
patients treated with mu opioid antagonist naltrexone
showed no significant difference relative to healthy con-
trols. In sum, buprenorphine may negatively affect ver-
bal memory, although evidence is still insufficient.
Stability of methadone patients’ cognitive function during
the first year in treatment
In this study, methadone patients show cognitive deficits
in all domains studied: attention, working memory and
verbal memory. Not all studies, however, have shown
attention deficits among them. Gordon found that
methadone-treated opioid-dependent patients outper-
formed controls in simple visual and visual multiple
choice reaction times [55]. Curran et al. found that 3 h
after methadone dose opioid-dependent patients in
methadone-aided opioid withdrawal actually had faster
simple reaction times than before the dose [56]. On the
other hand, in the Lintzeris et al study high dose of
methadone (150% of normal dose) was associated with
slower reaction times in OST patients [20]. Thus, the
issue whether methadone dose prolongs reaction times
in opioid-dependent patients is not fully resolved.
We found a stabile working memory deficit in both
complex working memory measures, the Letter-Number
Sequencing and the PASAT, in methadone patients. In
early study Gritz et al. found no deficit in methadone
patients in “simple” working memory test, the Digit
Span from the Wechsler scales, in which the items
needs to repeated without organizing them [57]. How-
ever, in a more recent study Darke et al. found medium
effect size difference between methadone patients and
healthy controls in the same test [5]. Interestingly, in
abstinent opioid-dependent patients “simple” working
memory seems to be spared while complex working
memory performance is impaired [58,59]. Thus, it
would be informative to compare methadone patients
against abstinent opioid-dependent patients using both
simple and complex working memory measures.
Methadone patients were inferior to healthy controls
in verbal memory. Also, in the Darke et al. study
opioid-dependent patients treated with methadone for a
minimum 5 months were impaired relative to healthy
controls in verbal memory [5]. However, in the Curran
et al. study opioid-dependent patients treated with
m e t h a d o n ef o ram i n i m u m6m o n t h sw e r eg i v e nt h e i r
normal dose, 33% increased dose, or placebo linctus;
and then tested 3-4 after the dose. No significant treat-
ment effect was seen, and the authors conclude that sin-
gle doses of methadone are devoid of verbal memory
effects among long-term methadone users. Thus, nega-
tive effect of methadone on verbal memory is not well-
confirmed.
Correlates of cognitive functioning in opioid substitution
treated patients
The most consistent finding of analyses of correlates of
cognitive functioning after 6 (T2) or 12 months (T3) in
treatment is that belonging to the methadone group
negatively associates with attention performance. How-
ever, as stated earlier in randomized or well-controlled
studies methadone patients, in general, have performed
at equal level than buprenorphine ones in tests measur-
ing attention. Thus, it is possible that patient selection
or other medication or substance abuse factor is affect-
ing the results in non-randomized studies, in which
methadone patients perform worse than buprenorphine
patients.
We hypothesized that the number of prescribed psy-
choactive drugs given to the patients would show nega-
tive correlations with performance in cognitive tests.
Our results, however, show three mild to moderate posi-
tive correlations between the number of psychoactive
drugs and verbal memory. Thus, the results do not con-
firm the hypothesis that the number of psychoactive
drugs as such would correlate negatively with cognitive
performance in OST patients. We hypothesized that
those with the high opioid substitution drug dose would
have higher BZD doses. The results were in line with
this hypothesis. Benzodiazepine use was very common
in both patient groups, and experimental studies have
shown that benzodiazepines, when given in combination
with opioid substitution drug may affect negatively
attention or verbal memory functioning [24]. Therefore,
we hypothesized that a negative correlation between the
BZD dose and cognitive measures would be seen.
Although one moderate negative correlation between
working memory measures and BZD dose is seen in our
clinical sample, this does not remain significant when
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substantial differences between test points and many
significant intercorrelations show that relationships
between medication variables and cognitive performance
are not easily discovered in clinical sample studies.
High frequency of substance abuse in the past month
was negatively associated with the working memory
measure with executive function component, the Letter-
Number Sequencing, at both test points. This finding is
line with studies reporting negative association between
working memory and recent substance abuse, possibly
affecting fluid intelligence in general [31,58,60]. In addi-
tion, frequency of substance abuse in the past month
correlates positively with BZD dose at both test points
(.36 - .50), and BZD dose correlated negatively with the
T2 Letter-Number Sequencing performance. Further-
more, the opioid substitution drug doses show moderate
or substantial correlations with the BZD doses. There is
temptation to suggest an association between the past
month frequent substance abuse, high opioid agonist
dose, high BZD dose, and impaired working memory
performance. Yet, our data do not allow controlling for
all these intercorrelations.
The hypothesis of negative effect of lifetime substance
abuse on cognitive performance was examined using
substance abuse onset ages and durations of abuse as
correlates for cognitive performance. Some negative cor-
relations emerged, but these were moderate at best.
Demographic variables have been shown to be impor-
tant correlates for cognitive performance in opioid-
dependent patients [10,36,37]. In our study, the only
consistent finding is the positive correlation between
Verbal IQ measured by the vocabulary test and verbal
memory. This relationship is not surprising because
vocabulary and verbal memory correlate moderately in
normal and clinical populations [61,62].
Limitations
The main limitation of part I of this study is the fact
that, while the opioid-dependent patient groups were
comparable to each other in variables of interest, our
healthy comparison group had hardly any medication or
substance abuse. Although these differences relate to the
‘dark side’ of addiction [63] they limit the specificity of
our results. Some of the cognitive deficits seen in
patients may be premorbid or related to early-onset sub-
stance abuse [64,65]. In order to examine these ques-
t i o n sa n a l y s e so fc o r r e l a t i o n sw e r ed o n ei ne x t e n d e d
population in part II of our study.
Because of high drop-out rate in our study we could
not use statistical methods to test causal relationships
in part II. On the other hand, comparison of correla-
tions from two testing points gives possibility to evalu-
ate their reliability and consistency. In case of
prescription opioid drug, drug screen do not show
extra doses. Thus, it is possible that opioid doses are
not fully accurate. While much is known about the
pharmacological comparisons between different BZDs,
the values of BZD equivalent doses are approximations
instead of precise values [39]. Alcohol use estimates
may not be fully accurate. These estimates were based
on information given by the participants. Breath alco-
hol analyzer or other objective test was used only
when considered necessary. Finally, our results do not
imply that functional capacity of an opioid-dependent
patient could be determined on the basis of his/her
drug group. Instead, validation of cognitive test battery
t oaf u n c t i o n a lt a s k ,f o ri n s t a n c ed r i v i n gac a r ,a sw e l l
as exploration of non-cognitive factors is needed [66].
Only then individual assessment of the functional
capacity can be made.
Conclusions
In conclusion, our results show again that in non-rando-
mized clinical studies buprenorphine patients tend to
perform better than methadone patients. The results do
not support the idea that there would be substantial
negative associations with medication variables and cog-
nitive performance among patients in OST. A longitudi-
nal study of opioid substitution treated patients who
switch from buprenorphine to methadone or vice versa
would be ideal in detecting cognitive effects of these
drugs and the roles of other clinical variables.
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